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Abstract
Human melanoma cells are very resistant to treatment with chemotherapeutic agents, and melanoma shows poor
response to chemotherapeutic therapy. We describe a strong synergistic proapoptotic effect of the Bcl-2 family in-
hibitor ABT-737 and the standard antimelanoma drugs, namely, dacarbazine and fotemustine, and the experimental
agent, imiquimod. Experiments with human melanoma cells, keratinocytes, and embryonic fibroblasts showed that
all three agents activated the mitochondrial apoptosis pathway. ABT-737 on its own was ineffective in melanoma
cells unless Mcl-1 was experimentally downregulated. However, ABT-737 strongly enhanced the proapoptotic ac-
tivity of the chemotherapeutic drugs. Whereas cell death induction by all three agents involved the activity of both
BH3-only proteins, Bim and Noxa, the combination with ABT-737 overcame the requirement for Bim. However, the
synergism between ABT-737 and imiquimod or dacarbazine required endogenous Noxa, as demonstrated by experi-
ments with Noxa-specific RNAi. Surprisingly, although Bim was activated, it was unable to replace Noxa. Studies of
mitochondrial cytochrome c release using BH3 peptides confirmed that a main effect of dacarbazine, fotemustine,
and imiquimod was to neutralize Mcl-1, thereby sensitizing mitochondria to the inhibition of other Bcl-2 family mem-
bers through ABT-737. ABT-737 is thus a promising agent for combination therapy for human melanoma. Impor-
tantly, the efficacy of this therapy depends on endogenous Noxa, and the ability of chemotherapeutic drugs to
activate Noxa may be a valuable predictor of their synergism with Bcl-2–targeting drugs.
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Introduction
Mitochondrial apoptosis is to a large extent regulated by the Bcl-2
family of proteins, which consists of three separate groups [1]. The
effector proteins, Bax and Bak, regulate the release of cytochrome c
and other apoptogenic factors from mitochondria to the cytosol. Bax
and Bak are activated consecutively to the activation of one or several
BH3-only proteins, such as Bim, Puma, Bad, or Noxa. The antiapop-
totic proteins Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1 inhibit apoptosis
by binding to BH3-only proteins or Bax/Bak [2]. How BH3-only
proteins activate Bax/Bak is still under dispute. The two molecular
models that have been put forward to explain this differ in partic-
ular on the point whether BH3-only proteins have to activate the
downstream effectors Bax and Bak (the “direct activation model”) or
whether the role of BH3-only proteins is confined to the neutraliza-
tion of antiapoptotic Bcl-2 proteins (as posited by the “displacement
model”) and apoptosis occurs by the default of these inhibitors [3–5].
The BH3 domain of BH3-only proteins can bind to antiapoptotic
Bcl-2 family proteins. Intriguingly, there are very significant differences
in affinities between the various pairings. Bim and Puma BH3 domains
can bind all antiapoptotic Bcl-2 proteins comparably well, whereas other
BH3-only proteins demonstrate a dichotomy in the system: especially
Bad can only bind to and neutralize Bcl-2, Bcl-xL, and Bcl-w but not
A1 orMcl-1, whereas Noxa binds onlyMcl-1 and A1, not the others [6].
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Because the basic cytochrome c release machinery seems intact in
at least nearly all tumors, compounds have recently been designed or
isolated that mimic BH3-only proteins in that they bind to the BH3
domain docking site in antiapoptotic Bcl-2 proteins and thereby
block the antiapoptotic function of these proteins [7–9]. Although
a number of such molecules have been described over the past years,
not all of them were confirmed as true Bcl-2 binders and antagonists
in a recent study [10]. These substances not only show promise as
antitumor agents but also proved to be valuable tools in dissecting
the mitochondrial apoptotic pathway. One substance, ABT-737,
was derived from a screen of small compounds that showed binding
affinity for the BH3 domain binding cleft of Bcl-xL [11]. ABT-737
has strong proapoptotic activity as a single agent against a number
of B-lymphoid malignancies as well as acute and chronic leukemia
cells and against small cell lung cancer cells (for review, see [12,13]).
Like Bad, ABT-737 binds with high affinity to antiapoptotic Bcl-2,
Bcl-xL, and Bcl-w but with much lower affinity to Mcl-1 or A1
[11]. This suggested that apoptosis resistance because of the high
expression of the Bcl-2 would be overcome, whereas high-level expres-
sion of Mcl-1 could protect tumor cells against ABT-737. Indeed, a
number of recent studies show consistently that Mcl-1 can confer re-
sistance to ABT-737, whereas experimental approaches that down-
regulate Mcl-1 sensitize tumor cells to ABT-737 (reviewed in [13]).
In a number of cell lines, ABT-737 has been found to induce apoptosis
synergistically with other chemotherapeutic agents [14]. The molecu-
lar mechanisms of this synergism are largely unknown. As ABT-737
targets Bcl-2-like proteins other than Mcl-1 (A1 seems not to be crit-
ical in cell lines tested so far), the role of a second, synergizing agent
likely involves neutralization of Mcl-1. Such neutralization could for
instance be achieved by the activation of Noxa, the displacement of
Bim or Bax/Bak from Bcl-2/Bcl-xL/Bcl-w (which should allow a
neutralization of Mcl-1 by released Bim), or by the direct targeting
of Mcl-1. A recent report suggests that synergism between ABT-737
and a synthetic cytotoxic retinoid in human acute lymphoblastic leu-
kemia cell lines involves the reactive oxygen species–dependent down-
regulation of Mcl-1 [15].
Disseminated malignant melanoma carries a very poor prognosis.
Although patients are routinely given chemotherapy, response rates
are typically below 10% [16], and this treatment resistance is associ-
ated with very low apoptotic responses of patient-derived melanoma
lines in vitro. Very recently, it was reported that human melanoma
lines are resistant to ABT-737 and that this resistance can be over-
come by tackling the Mcl-1–Noxa axis, either by down-regulating
Mcl-1 by RNAi or by up-regulating Noxa using a proteasome in-
hibitor [17].
We here report strong synergism of ABT-737 with two chemo-
therapeutic agents in clinical use (dacarbazine and fotemustine) and
one experimental agent (imiquimod [18,19]) in apoptosis induction
in human melanoma cell lines. Dacarbazine and fotemustine are both
alkylating substances from different substance classes and are both in
clinical use for disseminated melanoma [20]. Imiquimod is an entirely
different molecule that was developed as an immunostimulatory drug
but was later found to stimulate Toll-like receptors (TLR) 7 and 8 and
to induce apoptosis in a number of skin-derived tumors by an un-
known mechanism [21]. In analyzing the molecular mechanism of this
synergism between ABT-737 and different drugs, we use knockdown
and knockout cell lines (including other cell types) to show that both
Bim and Noxa play a role in these forms of apoptosis. Surprisingly, the
loss of Bim but much less the loss of Noxa could be compensated for
by ABT-737. Synergism of these cytotoxic drugs with ABT-737 thus
requires endogenous Noxa and the ability of cytotoxic drugs to acti-
vate Noxa may be an important predictor of their synergism with
BH3-only protein mimetics.
Materials and Methods
Cell Lines and Culture Conditions
1205Lu, 451Lu, WM35, and Sbcl2 human melanoma cells repre-
senting different stages of tumor progression (1205Lu and 451Lu
are from metastatic melanoma, WM35 and Sbcl2 are radial growth
phase melanomas [22,23]) were obtained from Dr. Meenhard Herlyn,
Wistar Institute, Philadelphia, and cultured in TU2% melanoma
medium containing 80% (v/v) MCDB153, 20% (v/v) Leibovitz’s
L-15, 2% (v/v) fetal calf serum (FCS; Biochrom, Berlin, Germany),
5 μg/ml insulin (Bovine, Sigma, Munich, Germany), 1.68 mM CaCl2,
and penicillin/streptomycin (Biochrom). HaCaT keratinocytes [24]
were cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% FCS and 1% (v/v) penicillin/streptomycin. Induction of
apoptosis was performed using imiquimod (InvivoGen, San Diego, CA)
at concentrations of 10 to 100 μg/ml (41.6-416 μM; 10 mg/ml stock
in DMSO). Fotemustine (Muphoran) was from Servier (Germany),
dacarbazine (DTIC) was obtained from Sigma. ABT-737 (5 mg/ml
stock in DMSO) was provided by Abbott Laboratories (Abbott Park,
IL). Mouse embryonic fibroblasts (MEFs) deficient for Noxa had been
isolated from Noxa-deficient mice by Dr. Andreas Strasser, Walter
and Eliza Hall Institute (WEHI), Melbourne, Australia, and immor-
talized by Dr. Christoph Borner, Albert-Ludwigs-University Freiburg,
Germany). Bax+/− Bak+/−, Bax−/− Bak−/−, Bax+/− Bak−/−, and Bax−/−
Bak+/− (immortalized with SV40 large Tantigen) were kindly provided
by Dr. David Huang, WEHI. 3T3-MEF cell lines isolated from Bim-
or Puma-deficient mice were established by Dr. Susanne Kirschnek,
Dr. Andreas Villunger (University of Innsbruck), andDr. Stefan Paschen.
SV40 large T-transformed MEF cells from Mcl-1–deficient mice
were generously provided by Dr. Joseph Opferman, St. Jude’s Chil-
dren’s Hospital, Memphis. All MEF cells were analyzed in com-
parison to wild type cells established at the same time and under
the same conditions. Mouse embryonic fibroblast cells were cul-
tured in Dulbecco’s modified Eagle’s medium containing 10% FCS
and 50 μM of 2-mercaptoethanol. All cultures were incubated under
standard culture conditions (37°C, 5% CO2).
Lentiviral Constructs and Lentiviral Infection
For generation of lentiviral Noxa RNAi constructs, RNAi sequences
N7 and N8 specifically targeting Noxa mRNA were cloned from
pSUPER-Noxi7 and pSUPER-Noxi8 (a kind gift fromDr. Eric Eldering,
Department of Experimental Immunology, Academic Medical Center
Amsterdam, the Netherlands [25]) in the GFP-expressing lentiviral
vector pLVTHM (Dr. Didier Trono, Lausanne) using restriction en-
zymes EcoRI/ClaI, yielding the plasmids pLVAWN7 and pLVAWN8.
Lentiviral constructs of shBIM and shScrambled have been de-
scribed previously [26]. Production of lentiviral particles was done
by transfecting 293 FT cells (Invitrogen, Basel, Switzerland) together
with packaging vectors pMD2.G and psPAX2 (Dr. Didier Trono,
Lausanne). HaCaT keratinocytes, 1205Lu and 451Lu melanoma cells
were infected with lentivirus carrying either a vector with scrambled
shRNA or a vector containing one Bim-specific shRNA fragment or
one of two Noxa-specific shRNA fragments. Cells with lentiviral
integration of shScrambled, shBim, and shNoxa were sorted for
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GFPexpression by FACS analyses. Knockdown of Mcl-1 was achieved
using 20 nM of specific siRNA using the manufacturer’s protocol
(Lipofectamine RNAiMax; Invitrogen).
Western Blot Analysis
Cells were extracted in buffer containing 1% Triton X-100, and
protein concentrations were estimated by the method of Bradford.
Protein samples were separated on 12.5% SDS polyacrylamide gels.
Antibodies against A1, Bcl-w (both Cell Signaling Technology, Danvers,
MA), Bcl-2, Bcl-xL, Mcl-1, cytochrome c (all BD Pharmingen, San Jose,
CA), Bim, tubulin (both Sigma), Noxa (Alexis, Farmingdale, NY), Puma
(Prosci, Poway, CA), Bax (clone 6A7), Bak (both Upstate Biotechnology,
Lake Placid, NY), cytochrome c oxidase subunit IV (CoxIV; MoBiTec,
Goettingen, Germany), caspase 8 (1C12 clone; Cell Signaling Tech-
nology), and GAPDH (Chemicon, NY) were used as suggested by the
manufacturers. Detection was performed with horseradish peroxidase–
conjugated secondary antibodies (specific to mouse [Dianova, Hamburg,
Germany] or rabbit [Sigma] immunoglobulin G [IgG]) and enhanced
chemiluminescence (Amersham Biosciences, Freiburg, Germany).
Detection of Apoptosis and Cell Death
To measure cell death, cells were stimulated using imiquimod, da-
carbazine, or fotemustine as indicated, collected, and were directly
stained by the addition of 10 mM propidium iodide (PI) and analyzed
within 1 hour by flow cytometry (FACSCalibur, Becton Dickinson);
positively staining cells were considered dead. Apoptosis was measured
by staining for active caspase 3 done with cells fixed for 20 minutes
at room temperature in freshly prepared 4% formaldehyde in PBS,
washed in PBS containing 0.5% BSA, and incubated with rabbit
anti–active caspase 3 antibody (1:500; Abcam, Cambridge, MA) in
staining buffer (PBS/0.5% BSA/0.5% saponin) for 30 minutes. Cells
were washed three times with PBS/BSA/saponin and stained with Cy5-
conjugated goat–antirabbit IgG (1:300; Dianova) secondary antibody
for 30 minutes. Cells were washed and analyzed by flow cytometry. For
caspase inhibition 50 μMzVAD-fmk (Bachem, Bubendorf, Switzerland)
was added 20 minutes before the treatment with imiquimod ± ABT,
dacarbazine, or fotemustine to block caspase-dependent apoptosis.
Detection of Bax and Bak Activation
HaCaT or melanoma cells were harvested after stimulation and
were stained using the activation-specific anti–active Bax antibody
(Clone3, 1:100; BD Pharmingen [27]). Fluorescein isothiocyanate
(FITC)–conjugated goat–antimouse IgG (1:300; Dianova) was used
as secondary antibody. For shNoxa, shBim, and shScrambled RNAi
knockdown cells expressing GFP, Cy5-conjugated goat–antimouse
IgG (1:300; Dianova) was used as secondary antibody. Staining for
active Bak was done using mAb1 (1:50; Calbiochem, Darmstadt,
Germany). Secondary antibodies and procedure were as previously
mentioned. Flow cytometry was performed with a FACSCalibur.
Subcellular Fractionation
Cells were harvested 24 hours after stimulation in mitochondrial
buffer, and the mitochondria were isolated as described earlier [28].
Subcellular localization of Bcl-2 family members was analyzed by
loading equal volumes of the mitochondria-enriched fraction, cytosolic
fraction, and the pellet fraction after 1 hour of ultracentrifugation
(UZ-pellet, 4°C at 260,000g) on 12.5% SDS polyacrylamide gels.
Cytochrome c Release Assay
Untreated or stimulated 1205Lu melanoma cells (0.15-0.2 ×
106 cells per sample) were harvested by trypsinization, washed with
PBS, and resuspended in 50 μl lysis buffer (20 mM HEPES pH 7.2,
100 mM KCl, 5 mMMgCl2, 1 mM EDTA, 1 mM EGTA, 250 mM
sucrose, 1× Roche Protease Inhibitor Mix) including 25 to 150 μg/ml
digitonin. Cells were incubated for 60 minutes at 30°C in the ab-
sence or presence of indicated BH3 peptides (100 μM) or ABT-737
(50 μM). Cells were then centrifuged for 10 minutes at 13,000g to
separate pellets and supernatants. Six times SDS sample loading buffer
was added to the supernatants, and the pellets were resuspended in
equal volumes of 1 × SDS sample loading buffer. The samples were
heated for 10 minutes at 95°C before the separation by SDS-PAGE.
After the protein transfer, the presence of cytochrome c in both pellets
and supernatants was detected with anti–cytochrome c antibody (BD
Pharmingen) and visualized by ECL Plus Western blot analysis de-
tection system from GE Healthcare (Munich, Germany). The BH3
peptides Bim, mNoxa, and Bad (confirmed by matrix-assisted laser
desorption/ionization time of flight and >90% pure) were obtained
from Biosynthan GmbH (Berlin, Germany). Peptides were dissolved
in 100% DMSO and stored as 10 mM stock solutions at −80°C. The
amino acid sequences used were MRPEIWIAQELRRIGDEFNA
(Bim), LWAAQRYGRELRRMSDEFVDSFKKG (Bad), and ELPPE-
FAAQLRKIGDKVYCT (Noxa).
Results
Four melanoma cell lines previously established from human tu-
mors were first tested for susceptibility to ABT-737 alone or in com-
bination treatment. Analysis of the expression levels of Bcl-2 family
proteins showed expression of all major antiapoptotic proteins, of
Bax and Bak, and the BH3-only proteins Bim, Puma, and Noxa.
No obvious differences between the cell lines were seen, perhaps with
the exception that Noxa and Mcl-1 were detectable in all four lines,
but their levels were noticeably lower in 1205Lu cells. Bim expres-
sion also varied somewhat between the cell lines, and Bim levels were
lower in all melanoma lines compared with the levels in HaCaT
human keratinocytes (Figure W1, A and B). All melanoma lines
showed considerable resistance to apoptosis induction by dacarbazine
and fotemustine with very little apoptosis after 24 hours of treat-
ment. Two cell lines displayed substantial cell death on 48 hours
of fotemustine treatment (cell death induction was statistically sig-
nificant for three of the four lines tested). Even relatively high con-
centrations of ABT-737 also induced only little apoptosis in the
melanoma cell lines, with the strongest response around 20% of cell
death in 1205Lu cells after 48 hours (Figure 1, A and B). However,
the combination of either dacarbazine or fotemustine and ABT-737
was active in inducing apoptosis in all cell lines. Although there was
some variation in efficiency, substantial cell death was seen in all mel-
anoma lines, ranging from approximately 40% to more than 80%
cell death at 48 hours of treatment (Figure 1, A and B).
Changes in Bcl-2 family proteins were monitored in the two cell lines
from metastatic melanoma, 451Lu and 1205Lu. We observed a small
increase in Bim levels by treatment with dacarbazine but not with
fotemustine in 1205Lu cells. In 1205Lu cells, substantial Noxa
induction was detectable on dacarbazine and fotemustine treatment,
whereas in 451Lu cells, Noxa was only induced on dacarbazine treat-
ment after 24 hours (Figure 1C). Noxa induction occurred through
de novo gene induction because it was blocked by the translational
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inhibitor cycloheximide (Figure 1D). There was no consistent change
in Puma levels. An inverse correlation of the levels of Noxa and
Mcl-1 has, in many cases, been observed. However, in most experi-
ments, no reduction of Mcl-1 was seen on treatment with either agent
(Figure 1C).
A similar pattern was observed in cells treated with imiquimod.
Imiquimod was developed as a small molecule immune modifier that
was found to activate myeloid cells through TLR7 and TLR8 [29]
but was later described to be able to induce apoptosis independently
of these receptors [18]. Imiquimod shows great promise for the local
treatment of some types of skin cancer and may even be useful for
the topical treatment of melanoma [21].
Although imiquimod has been reported to induce apoptosis in
some melanoma cells [19], we found only insubstantial induc-
tion of cell death in our panel of cell lines treated with imiquimod
alone. However, high levels of apoptosis were observed in all cell lines
when treated with the combination of imiquimod and ABT-737
(Figure 2, A and B). When the levels of Bim and Noxa were monitored
Figure 1. Synergistic killing of melanoma cells by dacarbazine or fotemustine and ABT-737. 1205Lu, 451Lu, WM35, and Sbcl2 melanoma
cells were either incubated with solvent or with ABT-737 (ABT; 1 μM) alone or together with dacarbazine (300 μg/ml) or fotemustine
(50 μg/ml) for 24 (A) or 48 hours (B). Apoptosis/cell death was measured by staining for active caspase 3 (24 hours) and PI (48 hours).
Data represent means ± SEM of three independent experiments. *P < .05 compared with solvent control; **P < .05 compared with
the corresponding dacarbazine or fotemustine concentration alone. In two independently performed experiments, PI staining could be
completely blocked by adding 50 μM zVAD-fmk before treatment with ABT-737 (1 μM) plus dacarbazine or fotemustine (data not shown).
(C) Western blot analysis of whole-cell lysates showing the levels of Bim, Noxa, Puma, Bcl-2, and Mcl-1 expression in 1205Lu and
451Lu melanoma cells 24 hours untreated or treated with dacarbazine (300 μg/ml) or fotemustine (50 μg/ml). The immunoblots show
representative results from three independent experiments. (D) Western blot analysis of whole-cell lysates from 1205Lu and 451Lu mela-
noma pretreated for 2.5 hours with cycloheximide (CHX, 2.5 μg/ml) before adding dacarbazine (300 μg/ml) or fotemustine (50 μg/ml)
for additional 24 hours. Tubulin and GAPDH were used as a loading control. The immunoblots show representative results from two
independent experiments.
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during treatment with imiquimod, a slight induction of Bim levels
was observed in two cell lines (1205Lu and Sbcl2) but not the other
two. More consistently, a small up-regulation of Noxa levels was seen
in all four lines (Figure 2C ). Induction of Noxa was again blocked
by cycloheximide in the tested 1205Lu melanoma cell line (Fig-
ure 2D). A corresponding decrease in Mcl-1 levels was observed
in three of the four lines (Figure 2C ). These results indicated that
up-regulation of endogenous Noxa by chemotherapeutic agents
might contribute to the sensitization of melanoma cells to ABT-737.
The slight up-regulation of Bim might indicate that this protein is
also involved.
To test for the contribution of Bim and Noxa directly, polyclonal
cell lines with Bim- or Noxa-specific shRNA were established for the
cell lines 451Lu and 1205Lu. Substantial reduction in the protein
expression levels was achieved by the expression of the shRNA spe-
cific for Bim or Noxa (Figure 3A). As shown in Figure 3B, there was
no protection by the reduction in Bim levels against apoptosis in-
duced by imiquimod plus ABT-737. However, both cell lines showed
significant protection against apoptosis induced by imiquimod/
ABT-737 when Noxa-specific shRNA was expressed (Figure 3B). This
protection was reflected by a reduced activation of Bax and Bak in cells
expressing Noxa-specific but not Bim-specific shRNA (Figure W2).
Dacarbazine alone induced relatively little apoptosis in these cells
(Figure 3, C and D). However, a contribution of both Bim and
Noxa to dacarbazine-induced cell death was detectable at 48 hours
of treatment (Figure 3D). Intriguingly, including ABT-737 com-
pletely removed the requirement for Bim but not for Noxa because
the Noxa knockdown still showed protection against the combina-
tion but not the Bim knockdown (Figure 3,C andD). The synergism of
ABT-737 with these two drugs therefore required the activity of endog-
enous Noxa protein.
The results were similar although not identical for apoptosis in-
duction with fotemustine. At 24 hours of treatment, knockdown of
either Bim or Noxa led to significant protection when fotemustine
was used on its own (Figure W3B). However, the requirement for Noxa
in the combination treatment of fotemustine plus ABT-737 was seen
only at very early times (at 6 hours of treatment) but not at 24 hours
(Figure W3).
Figure 2. Synergistic killing of melanoma cells by imiquimod and ABT-737. 1205Lu, 451Lu, WM35, and Sbcl2 melanoma cells were
either incubated with solvent (DMSO, 0.95%) or with ABT-737 (ABT; 1 μM) alone or with increasing concentrations (from left to right
5, 25, 50, 75 μg/ml) of imiquimod as indicated. After 6 (A) or 24 hours (B) of treatment, cells were collected and apoptosis/cell death was
measured by either staining for active caspase 3 (A) or staining for PI-positive cells (B), followed by flow cytometric analysis. Data rep-
resent means ± SEM of at least four (A) or three (B) experiments. *P< .05 compared with solvent control; **P< .05 compared with the
corresponding imiquimod concentration alone. (C) Western blot analysis of whole-cell lysates showing the levels of Bim, Noxa, and Mcl-1
expression in melanoma cells 24 hours after stimulation ± 75 μg/ml imiquimod. Tubulin was used as a loading control. In two inde-
pendently performed experiments, PI staining could be blocked by adding 50 μM zVAD-fmk before treatment with ABT-737 (1 μM) plus
75 μg/ml imiquimod (data not shown). (D) Western blot analysis of whole-cell lysates from 1205Lu melanoma pretreated for 2.5 hours with
cycloheximide (CHX, 2.5 μg/ml) before adding imiquimod (90 μg/ml) for additional 24 hours.
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Figure 3. A and B: Noxa but not Bim knockdown by RNAi protects melanoma cells against apoptosis induced by imiquimod or dacar-
bazine in the presence of ABT-737. (A) Immunoblot showing levels of Bim and Noxa expression in polyclonal 1205Lu and 451Lu cell
lines expressing shRNA specific for Bim or Noxa (two different sequences, N7 and N8) after 24 hours of stimulation with 50 μg/ml
imiquimod plus 1 μM ABT-737. Tubulin was used as a loading control. (B) Cells shown under A were treated for 24 hours with DMSO
(0.7%) or 50 μg/ml imiquimod plus ABT-737 (ABT; 1 μM), and cell death was assessed by staining with PI, followed by flow cytometric
analysis. 1205Lu− and 451Lu shScrambled controls were treated with 50 μM zVAD-fmk before stimulation with imiquimod plus ABT.
Data represent means ± SEM of five experiments. *P < .006; **P < .025 compared with scrambled control line. C and D: Apoptosis
induction and requirement for Bim or Noxa in 1205Lu melanoma cells treated with dacarbazine and the combination with ABT-737. (C)
Cells were treated with ABT-737 (ABT; 1 μM) for 24 hours together with dacarbazine (300 μg/ml), and cell death was assessed by stain-
ing for active caspase 3, followed by flow cytometric analysis. Data represent means ± SEM of at least three experiments. *P < .05;
**P < .005 compared with scrambled control. (D) Cells were treated for 48 hours with 300 μg/ml dacarbazine ± ABT-737 (ABT; 1 μM),
and cell death was measured by staining with PI and subsequent flow cytometry. Data represent means ± SEM of five experiments.
*P < .05; **P < .005 compared with scrambled control.
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ABT-737 can effectively neutralize Bcl-2, Bcl-xL, and Bcl-w but
not Mcl-1 or A1 [11]. The observed sensitization of melanoma cells
to ABT-737 by dacarbazine, fotemustine, and imiquimod therefore
suggested that the contribution of these latter drugs to the synergistic
effect is the neutralization of Mcl-1. Indeed, knockdown of Mcl-1 in
the two melanoma lines tested was sufficient to sensitize the cells to
single-agent treatment with ABT-737 (Figure 4A). This further sup-
ports a model where dacarbazine, fotemustine, and imiquimod cause
the inhibition of antiapoptotic Bcl-2 family members, critically in-
cluding Mcl-1. The combination with ABT-737 then can inhibit the
complete group of antiapoptotic Bcl-2 family proteins.
To test this hypothesis directly at the mitochondrial level, we used
peptides consisting of the BH3 domains of BH3-only proteins and
analyzed mitochondrial sensitivity of permeabilized melanoma cells
(the cell line 1205Lu was used for these experiments). In untreated
1205Lu cells, only the BH3 peptide derived from Bim (which can
target all antiapoptotic Bcl-2 proteins [6]) caused the release of cyto-
chrome c. Neither Bad peptide (targeting Bcl-2, Bcl-xL, and Bcl-w)
nor Noxa peptide (targeting Mcl-1 and A1) had this activity. ABT-
737 on its own likewise had no effect, whereas the combination of
Bad or ABT-737 together with Noxa was able to induce release (Fig-
ure 5). Cytochrome c release from mitochondria of melanoma cells
was thus achieved by a combination of agents that bound to all anti-
apoptotic Bcl-2 proteins.
Cells were then pretreated with dacarbazine, fotemustine, or imi-
quimod for 24 hours and subjected to the same assay. In all cases,
these pretreated, permeabilized cells were sensitive to ABT-737 on its
own (and to Bad peptide, which was tested for fotemustine-pretreated
cells; Figure 5). Taken together, these data provide strong evidence
that dacarbazine, fotemustine, and imiquimod can neutralize Mcl-1
through endogenous Noxa (and these agents may also contribute to
the inactivation of other antiapoptotic Bcl-2 proteins). ABT-737 can
then neutralize the remaining Bcl-2–like proteins, leading to the release
of cytochrome c.
These results showed a surprisingly important role for endogenous
Noxa in sensitizing melanoma cells to apoptosis induced by ABT-
737. The situation in melanoma is complicated by the fact that single
agent shows only little apoptosis-inducing activity, and we therefore
looked for other cell types where apoptosis would be induced in the
absence of ABT-737 and the contributing BH3-only proteins and
found that both MEFs and HaCaT human keratinocytes died when
treated with imiquimod alone. The contribution of Bim and Noxa to
imiquimod-induced apoptosis was first confirmed in MEFs. Mouse
embryonic fibroblast cells from mice lacking either Bim or Noxa
but not cells from mice lacking Puma were significantly protected
against imiquimod-induced apoptosis, whereas the loss of Mcl-1 in-
creased sensitivity (Figure W4A). Although MEF cells lacking both
Bax and Bak were protected against imiquimod-induced apoptosis,
cells expressing only either Bax or Bak died in a way comparable
to wild type MEF cells (Figure W4B). Imiquimod is a known ligand
for TLR7 and TLR8. To confirm the suspected independence of
imiquimod-induced apoptosis of TLR, we also tested MEF cells lack-
ing the essential signaling adaptor of TLR7/8, MyD88. These cells
showed normal sensitivity toward imiquimod (Figure W4B); imi-
quimod thus induces apoptosis independently of TLR.
As shown in Figure 6A, imiquimod on its own induced substantial
apoptosis in HaCaT human keratinocytes. Induction of apoptosis
was accompanied by a clear induction of Noxa protein but a reduc-
tion of Bim levels. Mcl-1 levels did not change (Figure 6B). Subcel-
lular fractionation showed an accumulation of Noxa at mitochondria,
coincident with a cytosolic depletion of Bax (Figure 6C ), suggesting
an involvement of Noxa in imiquimod-induced apoptosis also in
HaCaT cells. Stable cell lines were then generated that expressed
shRNA directed against Bim or Noxa. These cell lines showed a clear
reduction of the target proteins as assessed by Western blot anal-
ysis (Figure 7A). As shown in Figure 7B, although up-regulation was
seen only for Noxa but not for Bim (Figure 6B), the loss of either
Bim or Noxa conferred significant protection against imiquimod
treatment. Reduction in either Bim or Noxa by RNAi reduced the
imiquimod-dependent activation of both Bax and Bak (Figure W5)
suggesting that both Bax and Bak were activated consecutively to the
activation of Bim or Noxa by imiquimod. As in melanoma cells,
ABT-737 was ineffective on its own but showed strong synergism
with imiquimod in terms of apoptosis induction inHaCaT cells. Again,
the requirement for Bim was overcome by ABT-737 but not the re-
quirement for Noxa (Figure 7C ). These results thus confirm in a
different cellular context that endogenous Noxa is required for syn-
ergistic apoptosis induction by ABT-737 and imiquimod. Whereas
both Bim and Noxa were involved, ABT-737 was able to replace
Bim but not Noxa, suggesting the surprising conclusion that Noxa
Figure 4. Knockdown of Mcl-1 sensitizes 1205Lu and 451Lu mel-
anoma cells to ABT-737. Cells were transiently transfected with
control (Ctr) and Mcl-1–specific siRNA. At 24 hours after transfec-
tion, cells were treated without (DMSO) or with 1 μM ABT-737 for
24 hours and assayed for Mcl-1 knockdown by Western blot anal-
ysis (A) or PI-positive cells (B). Data represent means ± SEM of at
least three experiments. *P < .04 compared with control plus
ABT-737. Note that in two independently performed experiments,
PI staining could be completely blocked by adding 50 μM zVAD-
fmk before treatment with ABT-737 (1 μM, data not shown).
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Figure 5. Pretreatment of 1205Lu cells with fotemustine, dacarbazine, and imiquimod sensitizes mitochondria for cytochrome c release
by ABT-737. 1205Lu cells were pretreated for 24 hours with 50 μg/ml fotemustine, 300 μg/ml dacarbazine, 50 μg/ml imiquimod, or
solvent. Digitonin-permeabilized cells were incubated for 60 minutes at 30°C with solvent (DMSO), BH3 peptides (100 μM), or ABT-
737 (50 μM). Reaction were centrifuged, and supernatant (S, containing released cytochrome c) and pellet (P) fractions (containing
mitochondria-bound cytochrome c) were probed with an anti–cytochrome c antibody.
Figure 6. Induction of apoptosis and levels and localization of Bcl-2 proteins in HaCaT keratinocytes during imiquimod treatment. (A)
Cells were treated with DMSO alone (solvent control, 1%) or with varying concentrations of imiquimod (10-100 μg/ml) for 24 hours, and
apoptosis was assessed by staining for active caspase 3, followed by flow cytometric analysis. zVAD-fmk (50 μM) was added 20 min-
utes before the addition of 100 μg/ml imiquimod. Data represent means ± SEM of three experiments. *P < .05 compared with solvent
control. In parallel, Bax activation was monitored by flow cytometry after staining with anti–active Bax/FITC–conjugated goat–antimouse
IgG. Bak activation was detected by staining with anti–active Bak/FITC–conjugated goat–antimouse IgG. Representative dot blots are
shown. Values represent ± SEM of at least four independent experiments. (B) Western blot analysis showing levels of BimEL, Puma,
Noxa, and Mcl-1 in whole-cell lysates after 24 hours of treatment with 100 μg/ml imiquimod or with 1% DMSO (solvent control). Tubulin
was used as a loading control. Three separate experiments gave similar results. (C) Localization of Bcl-2 family proteins in HaCaT cells
after imiquimod treatment. Cells were incubated without (1% DMSO) or with 100 μg/ml imiquimod. At 24 hours later, cells were col-
lected and subjected to fractionation experiments. Caspase 8 was used as a cytosolic, CoxIV as a mitochondrial loading control. The
immunoblots are representatives of three separate experiments.
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fulfills a molecular function that cannot be performed by Bim in this
situation.
Discussion
ABT-737 has shown efficacy in a range of tumor cells. This study
shows strong proapoptotic synergism of ABT-737 and two standard
drugs and one experimental agent in melanoma cells. This is encour-
aging from a clinical point of view as disseminated melanoma is
almost completely resistant to chemotherapy, and the inclusion of
ABT-737 in a treatment regimen is promising. Remarkably, endog-
enous Noxa protein made a significant contribution to this syner-
gistic effect and was indispensable for full apoptosis induction not
only by the single agents but also by the combination of ABT-737
and either imiquimod or dacarbazine. In the case of fotemustine sin-
gle treatment, Noxa contributed early on but was dispensable to later
time points. One important point is thus that Noxa can do something
that Bim is unable to do. This was clearest in the case of HaCaT cells
(where imiquimod killed in the absence of ABT-737) but similar in
melanoma cells. Knockdown of either Bim or Noxa conferred similar
protection against imiquimod (or dacarbazine in melanoma), clearly
indicating the involvement of both proteins. However, ABT-737 could
replace Bim but not Noxa.
Noxa is an intriguing BH3-only protein in that it seems to bind
exclusively to Mcl-1 and A1 (A1 is expressed at low levels only in
many tumor cells [10], although it was easily detectable in melanoma
cells; Figure W1). Noxa-deficient mice have, as far as investigated,
only relatively subtle defects, although a role of Noxa in apoptosis in-
duced by adriamycin in transformed MEF cells [30] to UV light–
induced apoptosis in the skin [31] and in apoptosis in activated T cells
[25,32] has been established. Noxa can bind to and neutralize Mcl-1,
and this binding can trigger the proteasomal destruction of Mcl-1
[33], whereas other Mcl-1–neutralizing ligands fail to trigger degra-
dation [34,35]. The most important function of Noxa may thus be
the neutralization/degradation of Mcl-1. Noxa was involved in apop-
tosis induced by imiquimod and dacarbazine, whereas its role was less
pronounced in fotemustine-induced apoptosis. In case of imiquimod
in three of the four tested melanomas, we could see a small reduc-
tion of Mcl-1, whereas dacarbazine and fotemustine induced degra-
dation of Mcl-1 in some but not all the experiments. Because Noxa
is very likely induced and codegraded with Mcl-1, the levels of both
proteins will probably be determined not only by their synthesis but
also by the rate of their degradation. The actual level of the proteins
may therefore not be a perfect indicator of the role of both Noxa
and Mcl-1.
Figure 7. Bim- or Noxa-specific RNAi protects HaCaT cells from
imiquimod-induced apoptosis. (A) Immunoblot of HaCaT cells
showing Bim and Noxa expression in polyclonal lines stably ex-
pressing shRNA directed against Bim or Noxa (two different se-
quences, N7 and N8) or a control shRNA (scrambled anti-Bim
sequence) after 24 hours of stimulation with 100 μg/ml imiquimod.
Tubulin was used as a loading control. (B) The cells shown under
A were treated for 24 hours with DMSO (1%) or 100 μg/ml imi-
quimod, and cell death was assayed by staining with PI, followed
by flow cytometric analysis. Data represent means ± SEM of five
experiments. *P = .04, specific constructs versus scrambled con-
trol. (C) HaCaT RNAi cells were treated for 18 hours with DMSO
(0.95%, solvent), ABT-737 (ABT; 1 μM), imiquimod (75 μg/ml), or
imiquimod plus 1 μM ABT-737. Cell death was assessed by PI
staining followed by flow cytometric analysis. Data represent
means ± SEM of three experiments. *P < .0002, shNoxa versus
shBim cells. Western blots (inset) show induction of Noxa with
75 μg/ml imiquimod 18 hours after induction in HaCaT. Tubulin
served as a loading control.
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Although Bim clearly plays a role in apoptosis induced by imiquimod,
dacarbazine, and fotemustine, it could be replaced by ABT-737. Be-
cause ABT-737 cannot neutralize Mcl-1, this implies that Bim is also
unable to neutralize Mcl-1 in this situation. This is very surprising be-
cause Bim has been consistently found to be able to bind to Mcl-1
(the Bim BH3 domain has in fact a 10-fold higher affinity to Mcl-1
compared with the Noxa BH3 domain [6]). When Mcl-1 was immu-
noprecipitated from cells untreated or treated with dacarbazine with
or without ABT-737, Noxa was coprecipitated but not Bim (data
not shown). This suggests that Bim, in this situation, is unable to
bind to Mcl-1. Although this was unexpected, the results are consis-
tent in the sense that Bim cannot functionally replace Noxa because
it cannot bind to Mcl-1. What exactly Bim does when activated by
these drugs is not clear. It should be pointed out that there was no
induction of Bim by imiquimod or fotemustine and only some in-
duction by dacarbazine in one of two tested cell lines. Bim therefore
contributes to apoptosis induced by these agents without an increase
in its levels. Although Bim-induced apoptosis is often accompanied
by an increase in Bim abundance [36], this is not essential, and situa-
tions have even been identified where an increase of Bim levels was
associated with a reduction in apoptosis [37]. It seems therefore likely
that Bim activation includes some unidentified posttranslational ac-
tivation event.
Our data are consistent with the view that two separate legs of the
Bcl-2 machinery have to be targeted before Bax and Bak are activated
[4,6]. This was particularly clear in the experiments where we used
BH3 peptides to study mitochondrial cytochrome c release. Whereas
in untreated cells the combination of Noxa peptide and ABT-737 (or
Bad peptide) was required for cytochrome c release, pretreatment
with dacarbazine, fotemustine, or imiquimod rendered mitochondria
susceptible to ABT-737 alone. All results thus suggest that, in terms
of synergism with ABT-737, the most important functional element
of these drugs is to activate Noxa and thereby to neutralize Mcl-1.
The reliance on Noxa was different between the agents used, with
fotemustine requiring Noxa contribution in the absence but not
the presence of ABT-737 (although Noxa was required for full apop-
tosis at early stages). Perhaps fotemustine is able to activate additional
BH3-only proteins that would contribute to the neutralization of
Mcl-1 or more effectively inactivate other Bcl-2–like proteins.
It is very difficult to achieve a treatment response in disseminated
human melanoma, and this difficulty is reflected by the poor apop-
totic response to chemotherapeutic agents of melanoma cell lines
in vitro. However, combination of such drugs, including the experi-
mental agent imiquimod, with ABT-737 shows promise for future
therapy protocols. Our data provide evidence that the ability of a
drug to activate endogenous Noxa is a predictor of its synergism with
the new class of agents targeting Bcl-2/Bcl-XL/Bcl-w, such as ABT-
737. For future combination therapies with these new agents, it may
well be worthwhile to reexamine therapeutic drugs that are inefficient
on their own. Potent Noxa inducers might be uncovered in such a
screen, which are ineffective as single agents but could be very effec-
tive when combined with Bcl-2–targeting drugs.
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Figure W1. Expression profile of proapoptotic and antiapoptotic proteins in melanoma cell lines. (A) Whole-cell lysates were prepared from
1205Lu, 451Lu, WM35, and Sbcl2 cells, and equal amounts of protein were loaded and run on 12.5% SDS-PAA gels. Tubulin served as a
loading control. All Western blots are representatives of three independent experiments. (B) Western blot analysis of whole-cell lysates
showing the levels of Bim expression in HaCaT keratinocytes in comparison to melanoma cells. *Protein of unknown origin.
Figure W2. Knockdown of Noxa protects from imiquimod-induced activation of Bax and Bak in 451Lu melanoma cells. Cells were treated
with DMSO (0.7%) or 50 μg/ml imiquimod plus ABT-737 (ABT; 1 μM) for 24 hours. Staining of active Bax and Bak in 451Lu scrambled, Bim,
and NoxaN8 RNAi knockdown cells was performed as described in Figure W3. The percentages of active Bax represent means ± SEM of
three experiments. *P < .05 compared with shScrambled. Staining for active Bak was performed once.
Figure W3. Requirement for Bim or Noxa in 1205Lu melanoma
during apoptosis induced by fotemustine and in combination with
ABT-737. Cells were treated for 6 (A) or 24 hours (B) with fotemus-
tine (50 μg/ml) alone or in combination with ABT-737 (1 μM), and
cell death was assessed by staining for active caspase 3 (A, B),
followed by flow cytometric analysis. Data represent means ±
SEM of at least four experiments. *P < .05; ** P < .005 compared
with scrambled control.
Figure W4. Loss of Bim or Noxa affords protection against imiquimod-induced killing of MEF cells. (A) Mouse embryonic fibroblast cells
from Bim, Noxa, Mcl-1, and Puma knockout (KO) mice and their corresponding wild type cells (WT) were treated for 19 hours with
DMSO (1%) or 100 μg/ml imiquimod, and apoptosis was assessed by staining for active caspase 3, followed by flow cytometric anal-
ysis. Where indicated, 50 μM zVAD-fmk was added before stimulation. Data represent means ± SEM of at least three independent
experiments as indicated (n). *P < .04 significantly less or more apoptosis compared with the equivalent wild type (WT). (inset)
Whole-cell lysates of MEF NoxaWT cells 18 hours after stimulation with 100 μg/ml imiquimod (+) or with 1% DMSO were tested by
Western blot analysis for Bim and Mcl-1 expression. Tubulin served as a loading control. Similar results were obtained in two separate
experiments. (B) Bax and Bak can both mediate imiquimod-induced killing in MEF cells, but MyD88 is not required. Bax+/− Bak+/−
(labeled WT), Bax−/− Bak−/− (DKO), Bax−/− Bak+/− (Bax KO), Bax+/− Bak−/− (Bak KO), MyD88 wild type, and knockout MEFs were
incubated with 75 μg/ml imiquimod or DMSO (0.75% alone) alongside the respective wild type cells. At 40 hours after stimulation, cells
were collected and stained with active caspase 3 followed by flow cytometric analysis. Data represent means ± SEM of at least three
experiments. *P < .05, significantly less apoptosis compared with WT MEFs incubated with imiquimod.
Figure W5. Knockdown of Bim or Noxa protects HaCaT keratinocytes from imiquimod-induced activation of Bax and Bak. Cells were
treated with DMSO alone (solvent control, 1%) or with 100 μg/ml imiquimod for 24 hours, and Bax activation was monitored by flow
cytometry after staining with anti–conformationally changed Bax (Clone3)/Cy5–conjugated goat–antimouse IgG. In parallel, Bak activa-
tion was detected using flow cytometry after staining with anti–conformationally changed Bak (AB-1)/Cy5–conjugated goat–antimouse
IgG. Results are given for two separate experiments and one representative dot blot.
